Fujihara, Yoshitaka 1) The RECIPIENT should read <a href='http://en.brc.riken.jp/news/gfp_conclude.shtml' target="_blank"> the GFP Transfer License contracted between the RIKEN BRC and GE Healthcare Bio-Sciences.</a>. 2) In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Transgenic Res. 2013;22:195-200) designated by the approver is required. 3) The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of from the DEPOSITOR. 4) The RECIPIENT must contact the DRPOSUTOR in the case of application for any patent or commercial use based in the results from the use of the BIOLOGICAL RESOURCE. 5) RECIPIENT whish ants to use the BIOLOGICAL RESOURCE for the purpose other than education or non-for-profit research is requested to enter into a MTA with Osaka University. Okabe, Masaru Mouse embryonic stem (ES) cell line derived from C57BL/6NCr. <a href=' http://cell.brc.riken.jp/en/wp-content/uploads/pdf/AES0182_HP.pdf' target="_blank"> Expressing EGFP. </a> マウス胚性幹細胞株。C57BL/6NCr由来。GFP発現細胞株。<a href=' http://cell.brc.riken.jp/ja/wp-content/uploads/pdf/AES0182_HP.pdf' target="_blank">EGFP発現プラスミドについて</a>。 マウス胚性幹細胞株。C57BL/6NCr由来。GFP発現細胞株。<a href=' https://cell.brc.riken.jp/ja/wp-content/uploads/pdf/AES0182_HP.pdf' target="_blank">EGFP発現プラスミドについて</a>。 1) <a href='http://ja.brc.riken.jp/news/gfp_conclude.shtml' target="_blank">GE Healthcare Bio-Sciences社とBRCとのGFP Transfer License 締結</a> を確認の上、手続きを取ること。 2) 利用者は、研究成果の公表にあたって寄託者の指定する文献 (Transgenic Res. 2013;22:195-200) を引用すること。 3) 利用者は、事前に承諾者に承諾を得ること。 4) 利用者が本件リソースを使用して得られた研究成果に基づき特許等の申請及び事業活動を行う場合は、寄託者と別途協議を行う。 5) 非営利機関が非営利目的の教育･研究用に用いる場合以外は、大阪大学と別途MTAを締結すること。 AES0182 EGR-G101 Mouse embryonic stem (ES) cell line derived from C57BL/6NCr. <a href=' https://cell.brc.riken.jp/en/wp-content/uploads/pdf/AES0182_HP.pdf' target="_blank"> Expressing EGFP. </a>